Literature DB >> 17199022

Ganaxolone.

Virinder Nohria1, Earl Giller.   

Abstract

Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) (GNX) is the 3beta-methylated synthetic analog of allopregnanolone; it belongs to a class of compounds referred to as neurosteroids. GNX is an allosteric modulator of GABA(A) receptors acting through binding sites which are distinct from the benzodiazepine binding site. It has activity in a broad range of animal models of epilepsy. GNX has been shown to be well tolerated in adults and children. In early phase II studies, GNX has been shown to have activity in adult patients with partial-onset seizures and epileptic children with history of infantile spasms. It is currently undergoing further development in infants with newly diagnosed infantile spasms, in women with catamenial epilepsy, and in adults with refractory partial-onset seizures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17199022     DOI: 10.1016/j.nurt.2006.11.003

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  9 in total

Review 1.  Neurosteroids: endogenous regulators of the GABA(A) receptor.

Authors:  Delia Belelli; Jeremy J Lambert
Journal:  Nat Rev Neurosci       Date:  2005-07       Impact factor: 34.870

2.  Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group.

Authors:  K Laxer; D Blum; B W Abou-Khalil; M J Morrell; D A Lee; J L Data; E P Monaghan
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

3.  Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity.

Authors:  E P Monaghan; L A Navalta; L Shum; D W Ashbrook; D A Lee
Journal:  Epilepsia       Date:  1997-09       Impact factor: 5.864

4.  Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Authors:  R B Carter; P L Wood; S Wieland; J E Hawkinson; D Belelli; J J Lambert; H S White; H H Wolf; S Mirsadeghi; S H Tahir; M B Bolger; N C Lan; K W Gee
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

5.  Effect of ganaxolone on flurothyl seizures in developing rats.

Authors:  S Liptáková; L Velísek; J Velísková; S L Moshé
Journal:  Epilepsia       Date:  2000-07       Impact factor: 5.864

6.  Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial.

Authors:  J F Kerrigan; W D Shields; T Y Nelson; D L Bluestone; W E Dodson; B F Bourgeois; J M Pellock; L D Morton; E P Monaghan
Journal:  Epilepsy Res       Date:  2000-12       Impact factor: 3.045

7.  Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself.

Authors:  D S Reddy; M A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

8.  Neuroactive steroids have multiple actions to potentiate GABAA receptors.

Authors:  Gustav Akk; John R Bracamontes; Douglas F Covey; Alex Evers; Tim Dao; Joe Henry Steinbach
Journal:  J Physiol       Date:  2004-05-14       Impact factor: 5.182

9.  Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice.

Authors:  Rafal M Kaminski; Matthew R Livingood; Michael A Rogawski
Journal:  Epilepsia       Date:  2004-07       Impact factor: 5.864

  9 in total
  44 in total

Review 1.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

2.  Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model.

Authors:  Doodipala S Reddy; Michael A Rogawski
Journal:  Epilepsy Res       Date:  2010-02-20       Impact factor: 3.045

Review 3.  Infantile spasms: review of the literature and personal experience.

Authors:  Alberto Fois
Journal:  Ital J Pediatr       Date:  2010-02-08       Impact factor: 2.638

Review 4.  Neurosteroids and GABAergic signaling in health and disease.

Authors:  Georgina MacKenzie; Jamie Maguire
Journal:  Biomol Concepts       Date:  2013-02

5.  Synthesis and pharmacological evaluation of neurosteroid photoaffinity ligands.

Authors:  Pavel Y Savechenkov; David C Chiara; Rooma Desai; Alexander T Stern; Xiaojuan Zhou; Alexis M Ziemba; Andrea L Szabo; Yinghui Zhang; Jonathan B Cohen; Stuart A Forman; Keith W Miller; Karol S Bruzik
Journal:  Eur J Med Chem       Date:  2017-04-21       Impact factor: 6.514

6.  A randomized controlled trial of ganaxolone in posttraumatic stress disorder.

Authors:  Ann M Rasmusson; Christine E Marx; Sonia Jain; Gail M Farfel; Julia Tsai; Xiaoying Sun; Thomas D Geracioti; Mark B Hamner; James Lohr; Richard Rosse; Lanier Summerall; Jennifer C Naylor; Cristine Cusin; Ariel J Lang; Rema Raman; Murray B Stein
Journal:  Psychopharmacology (Berl)       Date:  2017-07-01       Impact factor: 4.530

7.  Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol.

Authors:  M J Ramaker; M M Ford; T J Phillips; D A Finn
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

8.  Temporal lobe epilepsy exacerbation during pharmacological inhibition of endogenous neurosteroid synthesis.

Authors:  Matteo Pugnaghi; Giulia Monti; Giuseppe Biagini; Stefano Meletti
Journal:  BMJ Case Rep       Date:  2013-02-19

Review 9.  The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment.

Authors:  Constance Guille; Susan Spencer; Idil Cavus; C Neill Epperson
Journal:  Epilepsy Behav       Date:  2008-03-17       Impact factor: 2.937

10.  Modifications of antiepileptic drugs for improved tolerability and efficacy.

Authors:  Cecilie Johannessen Landmark; Svein I Johannessen
Journal:  Perspect Medicin Chem       Date:  2008-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.